Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

被引:317
作者
Muranen, Taru [1 ]
Selfors, Laura M. [1 ]
Worster, Devin T. [1 ]
Iwanicki, Marcin P. [1 ]
Song, Loling [1 ]
Morales, Fabiana C. [2 ]
Gao, Sizhen [1 ]
Mills, Gordon B. [2 ]
Brugge, Joan S. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
基金
芬兰科学院;
关键词
CAP-INDEPENDENT TRANSLATION; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; INSULIN-RECEPTOR; AKT ACTIVATION; UP-REGULATION; PI3K PATHWAY; BREAST; INITIATION; APOPTOSIS;
D O I
10.1016/j.ccr.2011.12.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including BcI-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 78 条
  • [11] Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
    Cloughesy, Tim F.
    Yoshimoto, Koji
    Nghiemphu, Phioanh
    Brown, Kevin
    Dang, Julie
    Zhu, Shaojun
    Hsueh, Teli
    Chen, Yinan
    Wang, Wei
    Youngkin, David
    Liau, Linda
    Martin, Neil
    Becker, Don
    Bergsneider, Marvin
    Lai, Albert
    Green, Richard
    Oglesby, Tom
    Koleto, Michael
    Trent, Jeff
    Horvath, Steve
    Mischel, Paul S.
    Mellinghoff, Ingo K.
    Sawyers, Charles L.
    [J]. PLOS MEDICINE, 2008, 5 (01): : 139 - 151
  • [12] The PI3K Pathway As Drug Target in Human Cancer
    Courtney, Kevin D.
    Corcoran, Ryan B.
    Engelman, Jeffrey A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1075 - 1083
  • [13] Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Creighton, Chad J.
    Massarweh, Suleiman
    Huang, Shixia
    Tsimelzon, Anna
    Hilsenbeck, Susan G.
    Osborne, C. Kent
    Shou, Jiang
    Malorni, Luca
    Schiff, Rachel
    [J]. CANCER RESEARCH, 2008, 68 (18) : 7493 - 7501
  • [14] Modelling glandular epithelial cancers in three-dimensional cultures
    Debnath, J
    Brugge, JS
    [J]. NATURE REVIEWS CANCER, 2005, 5 (09) : 675 - 688
  • [15] Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner
    Debnath, J
    Walker, SJ
    Brugge, JS
    [J]. JOURNAL OF CELL BIOLOGY, 2003, 163 (02) : 315 - 326
  • [16] Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Debnath, J
    Muthuswamy, SK
    Brugge, JS
    [J]. METHODS, 2003, 30 (03) : 256 - 268
  • [17] Targeting PI3K signalling in cancer: opportunities, challenges and limitations
    Engelman, Jeffrey A.
    [J]. NATURE REVIEWS CANCER, 2009, 9 (08) : 550 - 562
  • [18] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    Engelman, Jeffrey A.
    Chen, Liang
    Tan, Xiaohong
    Crosby, Katherine
    Guimaraes, Alexander R.
    Upadhyay, Rabi
    Maira, Michel
    McNamara, Kate
    Perera, Samanthi A.
    Song, Youngchul
    Chirieac, Lucian R.
    Kaur, Ramneet
    Lightbown, Angela
    Simendinger, Jessica
    Li, Timothy
    Padera, Robert F.
    Garcia-Echeverria, Carlos
    Weissleder, Ralph
    Mahmood, Umar
    Cantley, Lewis C.
    Wong, Kwok-Kin
    [J]. NATURE MEDICINE, 2008, 14 (12) : 1351 - 1356
  • [19] Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
    Feldman, Morris E.
    Apsel, Beth
    Uotila, Aino
    Loewith, Robbie
    Knight, Zachary A.
    Ruggero, Davide
    Shokat, Kevan M.
    [J]. PLOS BIOLOGY, 2009, 7 (02) : 371 - 383
  • [20] The PERK/elF2α/ATF4 module of the UPR in hypoxia resistance and tumor growth
    Fels, Diane R.
    Koumenis, Constantinos
    [J]. CANCER BIOLOGY & THERAPY, 2006, 5 (07) : 723 - 728